<DOC>
	<DOCNO>NCT00436553</DOCNO>
	<brief_summary>This study evaluate effect combination therapy verteporfin photodynamic therapy ranibizumab visual acuity anatomic outcome compare ranibizumab monotherapy durability response observe patient choroidal neovascularization secondary age-related macular degeneration .</brief_summary>
	<brief_title>Efficacy/Safety Verteporfin Photodynamic Therapy Ranibizumab Compared With Ranibizumab Patients With Subfoveal Choroidal Neovascularization</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects either gender age 50 year old Subfoveal choroidal neovascularization ( CNV ) due agerelated macular degeneration ( AMD ) Choroidal neovascularization due cause AMD Prior treatment neovascular AMD study eye Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Age-related macular degeneration ; AMD</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>verteporfin</keyword>
	<keyword>ranibizumab</keyword>
</DOC>